New clinical trial data showing the arthritis drug Vioxx increases the risk of stroke and heart attack has prompted Merck to voluntarily pull it from the market. "We are taking this action because we believe it serves the best interest of patients," said Raymond Gilmartin, the company's chairman and CEO. Merck sold $2.5 billion worth of Vioxx in 2003.

Related Summaries